The human gut is a remarkable thing. Every week the intestines regenerate a new lining, sloughing off the equivalent surface area of a studio apartment and refurbishing it with new cells. For decades, researchers have known that the party responsible for this extreme makeover were intestinal stem cells, but it wasn't until this year that Scott Magness, PhD, associate professor of medicine, cell biology and physiology, and biomedical engineering, figured out a way to isolate and grow thousands of these elusive cells in the laboratory at one time. This high throughput technological advance now promises to give scientists the ability to study stem cell biology and explore the origins of inflammatory bowel disease, intestinal cancers, and other gastrointestinal disorders.

But it didn't come easy.

One Step Forward . . .

When Magness and his team first began working with intestinal stem cells some years ago, they quickly found themselves behind the eight ball. Their first technique involved using a specific molecule or marker on the surface of stem cells to make sure they could distinguish stem cells from other intestinal cells. Then Magness's team would fish out only the stem cells from intestinal tissues and grow the cells in Petri dishes. But there was a problem. Even though all of the isolated cells had the same stem cell marker, only one out of every 100 could "self-renew" and differentiate into specialized cells like a typical stem cell should. (Stem cells spawn cells that have specialized functions necessary for any organ to work properly.)

"The question was: why didn't the 99 others behave like stem cells?" Magness said. "We thought it was probably because they're not all the same, just like everybody named Judy doesn't look the same. There are all kinds of differences, and we've been presuming that these cells are all the same based on this one name, this one molecular marker. That's been a problem. But the only way to solve it so we could study these cells was to look at intestinal stem cells at the single cell level, which had never been done before."

Magness is among a growing contingent of researchers who recognize that many of the biological processes underlying health and disease are driven by a tiny fraction of the 37 trillion cells that make up the human body. Individual cells can replenish aging tissues, develop drug resistance, and become vehicles for viral infections. And yet the effects of these singular actors are often missed in biological studies that focus on pooled populations of thousands of seemingly "identical" cells.

Distinguishing between the true intestinal stem cells and their cellular look-a-likes would require isolating tens of thousands of stem cells and tracking the behavior of each individual cell over time. But Magness had no idea how to accomplish that feat. Enter Nancy Allbritton, PhD, chair of the UNC/NCSU Joint Department of Biomedical Engineering. The two professors met one day to discuss Magness joining the biomedical engineering department as an adjunct faculty member. And they did discuss it. And Magness did join. But the meeting quickly turned into collaboration. One of Allbritton's areas of expertise is microfabrication -- the ability to squeeze large devices into very small footprints. During their meeting, Allbritton showed Magness her latest creation, a device smaller than a credit card dotted with 15,000 tiny wells for culturing cells.

"It was like a light bulb went off, and I realized I was looking at the answer to a billion of our problems," Magness said.

Micro Magic

Each microwell is as thick as a strand of hair. By placing individual stem cells into the microwells, Magness and postdoctoral fellow Adam Gracz, PhD, could watch the cells grow into fully developed tissue structures known as mini-guts. Each microwell could be stamped with a specific address, which would allow researchers to track stem cells that were behaving as expected and those that weren't.

Read more:
A Single-Cell Breakthrough: newly developed technology dissects properties of single stem cells

HACKENSACK, N.J.and PETACH TIKVAH, Israel, March 18, 2015 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.

The following are specific details regarding BrainStorm's presentation:

Event:

ARM's Regen Med Investor Day

Date:

March 25, 2015

Time:

4:20 PM EST

Location:

See the original post:
BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York

Stem Cell Therapy- Sci Video2
Created using PowToon -- Free sign up at http://www.powtoon.com/join -- Create animated videos and animated presentations for free. PowToon is a free tool that allows you to develop cool...

By: Georgia McDonald

Read the rest here:
Stem Cell Therapy- Sci Video2 - Video

GERMANTOWN, Md., March 16, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) (the "Company" or "Neuralstem") today reported its financial results for the fourth quarter and year ended December 31, 2014.

"Neuralstem has progressed into a clinical development stage company focused on the central nervous system (CNS)," said Richard Garr, Neuralstem President and CEO. "During 2014 we added two established industry leaders as Independent Directors, Catherine Angell Sohn, Pharm.D. and Sandford Drexel Smith. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline. Mr. Smith is the former Executive Vice President of Genzyme Corporation. The Company moved forward two lead clinical assets: our small molecule neurogenic drug candidate NSI-189 and our spinal derived neural stem cell therapeutic candidate NSI-566. We established and/or grew clinical research programs with leading investigators at Emory University, University of California, San Diego (UCSD), University of Michigan and Massachusetts General Hospital. Our investigators published and presented proof of principle data in both lead assets as highlighted below. In 2015, we plan to begin clinical development of our NSI-189 small molecule drug in a second indication for the treatment of cognitive deficit from schizophrenia, and we plan to initiate a Phase II clinical trial for the ongoing development program for the treatment of major depressive disorder (MDD). The cell therapy programs in amyotrophic lateral sclerosis (ALS), chronic spinal cord injury (cSCI) and stroke will also move forward. We expect this to be another important year continuing our development and progress across both platforms."

2014 Clinical Program and Business Highlights

Neurogenic Small Molecule Platform Clinical Development

Cell Therapy Platform Clinical Development

NSI-566 spinal cord-derived stem cell therapy under development for the treatment of ALS

NSI-566 spinal cord-derived cell therapy under development for the treatment of cSCI

NSI-566 spinal cord derived stem cell therapy under development for the treatment of motor deficits in stroke

NSI-532.IGF second generation gene engineered cell therapy

2014 Business Highlights

Continued here:
Neuralstem Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results

MIAMI (PRWEB) March 17, 2015

GlobalStemCellsGroup.com has announced plans to participate in the 25th annual Argentine Congress of Aesthetic Medicine April 9 and 10 2015. More than 1,000 physicians from around the world will descend on Buenos Aires for the conference to learn and share new findings in aesthetic medicine.

Following the congress, Global Stem Cells Group and Estanislao Janowski, M.D., a plastic surgeon specializing in stem cell application in aesthetic and cosmetic medicine will conduct an intensive, hands-on course on stem cell harvesting, isolation and re-integration, to be held April 11. Janowski, a GSCG faculty member and long-time collaborator is the owner and president of Bioplastica, an aesthetic surgical center featuring the latest stem cell applications in cosmetic and anti-aging medicine.

This will be the third year Global Stem Cells Group participates in the conference, hosted by the Argentina Society of Aesthetic Medicine (SOARME). A soon-to-be-named GSCG faculty member will also deliver a keynote speech to congress attendees.

The international event, which will be held at the Catholic University of Argentina in Buenos Aires, will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. SOAME is a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOAME has the scientific support of the John F. Kennedy University in Buenos Aires and a host of national and international scientific organizations.

For more information visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Read more here:
Global Stem Cells Group to Participate in the 25th Argentine Congress of Aesthetic Medicine in Buenos Aires April 9-10 ...

Jeremy #39;s Stem cell therapy journey
This is a video about stem cells and stem cell therapy. Created by #39;Vivienne Armstrong #39;.-- Created using PowToon -- Free sign up at http://www.powtoon.com/join -- Create animated videos and...

By: Vivi Armstrong

Visit link:
Jeremy's Stem cell therapy journey - Video

Dr. Nathan Newman - Stem Cell Therapy and Regenerative Medicine
Dr. Nathan Newman is a Board Certified Dermatologist, a Cosmetic Surgeon, and a pioneer in stem cell therapy and Regenerative Medicine. He is world-renowned for his ground-breaking Stem Cell...

By: 110Seconds

Continued here:
Dr. Nathan Newman - Stem Cell Therapy and Regenerative Medicine - Video

Orange, California (PRWEB) March 17, 2015

The top stem cell therapy clinics in California, Telehealth, are now offering treatment for nonhealing wounds at three locations. The stem cell therapy for wound healing is being offered by Board Certified doctors at three separate locations in Orange, La Jolla and Upland. Call (888) 828-4575 for more information and scheduling.

Patients with diabetes, neuropathy and autoimmune disorders often find it difficult to heal even minor wounds. This may lead to diabetic ulcers and infections in the soft tissue and/or bone. At times, even the most rigorous conventional wound care fails to heal wounds sufficiently.

At Telehealth, stem cell therapy for nonhealing wounds has been showing exceptional results. Wounds that had basically been unresponsive to traditional methods have displayed quick results with healing when the procedures are performed. The regenerative medicine treatments involve either bone marrow derived stem cells or amniotic derived stem cells. Additional, PRP therapy is included in the treatment at times when necessary.

Along with helping to heal difficult wounds, stem cell therapy is also available for degenerative arthritis, chronic tendonitis, rotator cuff tears, ligament injuries, migraines and much more. Treatments are offered in Orange, Upland and a new La Jolla location by Board Certified doctors with extensive experience.

Most treatments are partially covered by insurance, which helps considerably to keep cost down. Call (888) 828-4575 for more information and scheduling.

Read the original:
Stem Cell Therapy Now Being Offered for NonHealing Wounds at Telehealth's Three Regenerative Medicine Clinics

Beverly Hills, California (PRWEB) March 17, 2015

Beverly Hills Orthopedic Institute is now offering stem cell procedures for the nonoperative treatment of shoulder labral tears. The procedures are outpatient, low risk, and very effective at helping patients avoid the need for surgery. Call Beverly Hills Orthopedic Institute at (310) 247-0466 for more information and scheduling.

Injuries to the shoulder may involve rotator cuff tendonitis, tears or labral injury. Stem cell therapy is typically effective for all of these conditions, and Dr. Raj has been having significant success with labral tears. Conventional treatment for labral tears is often unsuccessful, as they typically do not have sufficient blood supply.

Treatment with regenerative medicine offers the potential to avoid surgery and heal the tissues. The stem cell therapy includes either bone marrow or amniotic derived treatment. Both of these are outpatient and very low risk. Small studies have shown the effectiveness of stem cell treatment for joint arthritis, tendonitis, tendon tears, cartilage defects and labral tears.

The treating physician, Dr. Raj, is a Double Board Certified orthopedic surgeon Beverly Hills trusts, and excels in treating all kinds of sports injuries and arthritic conditions. He also serves as a Medical Correspondent for ABC News, along with receiving numerous LA TOP DOC and Top Doctors Southern California Awards.

To receive the best stem cell therapy in Los Angeles and Beverly Hills, call the Institute today at (310) 247-0466.

More:
Beverly Hills Orthopedic Institute Now Offering Stem Cell Therapy for Nonoperative Shoulder Labral Tears

A TEENAGER'S quest to find a bone marrow match and beat his leukaemia has inspired school friends to go on to save the lives of two perfect strangers.

Jack Coen and Joe Rowbottom, both 18, were at Bradford Grammar School when fellow pupil Alex Anstess, now 16, was first diagnosed with Acute Myeloid Leukaemia in 2012.

After hearing a talk in school about registering on the Anthony Nolan Bone Marrow register, they - and others - signed up and both of them have gone on to successfully donate stem cells.

Jack, from Ilkley, who donated in October last year after being found to be a perfect match for a patient needing a bone marrow transplant, said: I just thought if you have the opportunity to save someones life then why not? If I was in that position, Id want someone to do it for me.

"On the day, I thought about the other person receiving my stem cells and hoped I could give them more Christmases with their family. If I never make another good decision for the rest of my life, I have at least made one good and worthwhile decision by donating."

And Joe, from Yeadon, who donated his stem cells last month, said: It was so easy to spit in a tube and sign up. It was weird to think a stranger was dependent on me and yet its such a small thing to do. It was actually surprising something so simple could save someones life. Knowing Alex spurred me on to donate because I knew what the person was going through. Its great to see Alex back at school and proves the donor register does work.

Although Alex, of Cullingworth, had gone into remission after his 2012 diagnosis, the cancer returned in July last year and doctors broke the news that his life depended on a bone marrow transplant. It was The Anthony Nolan Trust that found him a perfect match and he had the procedure in September last year, helping him on the road to recovery.

His mum, Sue, said: I cannot describe the feeling of seeing that little bag of stem cells come in for Alex. We waited a long time for that moment and Ill never forget the relief we felt. Were so thankful to the donor who literally saved his life. Its absolutely brilliant that Jack and Joe have gone on to donate and help another family like ours."

Bradford Grammar headteacher Kevin Riley said: The school motto is Hoc Age which we usually translate as Just do it. What a wonderful example Jack and Joe are of that determination to help others. Im proud of them and the other students who have responded to the appeal.

If you are aged 16-30 and in good health you too can sign up to the Anthony Nolan register at anthonynolan.org. To find out more about the Register & Be a Lifesaver programme, email registerandbe@AnthonyNolan.org or call 0207 284 8213.

See the original post:
Teenager's quest to beat leukaemia inspires school friends to donate stem cells to help people in need

Stem cells are special cells that can turn into any kind of cells in the body. They serve as a repair system for the body. There are two main types of human stem cells: embryonic stem cells and adult stem cells.

Embryonic stem cells are cells that come from an unborn baby (embryo). Those are NOT the cells that are used for this product.LUMINESCEformulation uses technology derived from the study of Adult Stem Cells.

Stem cells communicate with tissue cells to induce repair. They produce many different growth factors and "communication" chemicals to do this.Dr Nathan Newmanhas been able to take stem cells in the lab, and separate them from the solution that holds the growth factors. This media is the foundation of theLUMINESCEproduct.

What is the relationship between growth factors and the stem cell technology?

The patent-pending technology ofLUMINESCEprovides for the delivery of key growth factors found in natural skin. As we age, the production of these growth factors within skin is reduced, and leads to wrinkling and thinning of the skin. By re-introducing these factors through the daily application ofLUMINESCE, damaged skin cells may be repaired, and skin tissue re-generated.

Stem cells are cells that have the ability to grow into any kind of cell in the body, and they rely on special signals to tell them what cells they will ultimately become. If you know the stem cell language, then you could communicate to the cells.

In this way, you could have stem cells that become new young skin cells, rebuild collagen, and deliver a new younger looking skin.

View original post here:
Stem Cells, Skin Care and Dr Newman | Skin Care

Steve Perrin, Ph.D., CEO and CSO, discusses why iPS technology is ready for drug discovery for today's ALS patients. Click here to learn why Steve believes TDI is uniquely suited to implement this technology in ALS research.

Fernando Vieira, M.D., director of research operations, discusses how iPS technology can be used to model sporadic ALS, help to identify sub-types of ALS patients and accelerate drug development as part of a comprehensive translational research program at ALS TDI.

Jessie St. Martin, associate scientist, talks about induced pluripotent stem cells (iPS cells) and their importance in ALS research. Jessie, a recent addition to the translational research team, will play an integral part in developing this program at ALS TDI. Click here to learn more about iPS cells.

Jenny Dwyer, board member, explains why your support of the iPS program at ALS TDI may have the ability to rapidly accelerate treatments for today's patients. Jenny was a longtime ALS caregiver of her husband, Pat. Together, they were advocates for ALS research. Click here to listen to her message.

Continued here:
Invest in iPS @ TDI | ALS Therapy Development Institute

Nova Cells Institute treatment Report, stem cell therapy, 562-916-3410
Nova Cells Institute stem cell treatment report shows success with spina bifida, lewy body dementia, cancer patients and more - visit http://www.novacellsinstitute.com to learn more.

By: NCIM

Original post:
Nova Cells Institute treatment Report, stem cell therapy, 562-916-3410 - Video

Orthopedic Stem Cell Therapy - Queens, New York
Benjamin Bieber MD of #CrossBayPMR in Howard Beach, New York has had great success with #stemcell therapy using your own fat cells. Avoid invasive #jointreplacement surgery and get back to...

By: Cross Bay Physical Medicine and Rehabilitation, P.C.

Read this article:
Orthopedic Stem Cell Therapy - Queens, New York - Video

The New Botox: Stem Cell Therapy Cream Reviews
http://buildingabrandonline.com/buildabrandwithjamalspikes/what-is-jeunesse/ The New Botox: Stem Cell Therapy Cream Reviews Stem cell therapy is the use of stem cells to treat or prevent a...

By: Jamal Spikes

See original here:
The New Botox: Stem Cell Therapy Cream Reviews - Video

Fauza D: Amniotic fluid and placental stem cells.

Best Pract Res Clin Obstet Gynaecol 2004, 18:877-891. PubMedAbstract | PublisherFullText

Parolini O, Alviano F, Bagnara GP, Bilic G, Bhring HJ, Evangelista M, Hennerbichler S, Liu B, Magatti M, Mao N, Miki T, Marongiu F, Nakajima H, Nikaido T, Portmann-Lanz CB, Sankar V, Soncini M, Stadler G, Surbek D, Takahashi TA, Redl H, Sakuragawa N, Wolbank S, Zeisberger S, Zisch A, Strom SC: Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells.

Stem Cells 2008, 26:300-311. PubMedAbstract | PublisherFullText

Pozzobon M, Ghionzoli M, De Coppi P: ES, iPS, MSC, and AFS cells. Stem cells exploitation for Pediatric Surgery: current research and perspective.

Pediatr Surg Int 2010, 26:3-10. PubMedAbstract | PublisherFullText

Miki T, Marongiu F, Dorko K, Ellis EC, Strom SC: Isolation of amniotic epithelial stem cells.

Curr Protoc Stem Cell Biol 2010, Chapter 1:Unit 1E 3. PubMedAbstract | PublisherFullText

Miki T, Strom SC: Amnion-derived pluripotent/multipotent stem cells.

Stem Cell Rev 2006, 2:133-142. PubMedAbstract | PublisherFullText

Follow this link:
Stem Cell Research & Therapy | Full text | Amnion-derived ...

Importance Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who receive approved disease-modifying therapies experience breakthrough disease and accumulate neurologic disability. High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, induce sustained remissions in early MS.

Objective To evaluate the safety, efficacy, and durability of MS disease stabilization through 3 years after HDIT/HCT.

Design, Setting, and Participants Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an ongoing, multicenter, single-arm, phase 2 clinical trial of HDIT/HCT for patients with RRMS who experienced relapses with loss of neurologic function while receiving disease-modifying therapies during the 18 months before enrolling. Participants are evaluated through 5 years after HCT. This report is a prespecified, 3-year interim analysis of the trial. Thirty-six patients with RRMS from referral centers were screened; 25 were enrolled.

Interventions Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.

Main Outcomes and Measures The primary end point of HALT-MS is event-free survival defined as survival without death or disease activity from any one of the following outcomes: (1) confirmed loss of neurologic function, (2) clinical relapse, or (3) new lesions observed on magnetic resonance imaging. Toxic effects are reported using National Cancer Institute Common Terminology Criteria for Adverse Events.

Results Grafts were collected from 25 patients, and 24 of these individuals received HDIT/HCT. The median follow-up period was 186 weeks (interquartile range, 176-250) weeks). Overall event-free survival was 78.4% (90% CI, 60.1%-89.0%) at 3 years. Progression-free survival and clinical relapse-free survival were 90.9% (90% CI, 73.7%-97.1%) and 86.3% (90% CI, 68.1%-94.5%), respectively, at 3 years. Adverse events were consistent with expected toxic effects associated with HDIT/HCT, and no acute treatment-related neurologic adverse events were observed. Improvements were noted in neurologic disability, quality-of-life, and functional scores.

Conclusions and Relevance At 3 years, HDIT/HCT without maintenance therapy was effective for inducing sustained remission of active RRMS and was associated with improvements in neurologic function. Treatment was associated with few serious early complications or unexpected adverse events.

Original post:
High-Dose Immunosuppressive Therapy and Autologous ...

Miracle stem cell therapy reverses multiple sclerosis
Latest research on stem cell therapy in curing MS.

By: Dulci Hill

Read more here:
Miracle stem cell therapy reverses multiple sclerosis - Video

Former Homeland Star David Harewood Has Written An Online Article Urging Black U.k. Residents To Sign Up To The Stem Cell Donor Register.

The actor has teamed up with stem cell charity Anthony Nolan and the African-Caribbean Leukaemia Trust (ACLT) to launch an appeal encouraging young, black Brits to donate bone marrow so leukaemia sufferers in ethnic minorities have a better chance of receiving pioneering stem cell treatment.

Harewood has written an online article for Independent.co.uk in which he details the stem cell donation process for the African-Caribbean community, and encourages them to take part.

He writes, "The black population is badly underrepresented on the bone marrow register compiled by the blood cancer charity Anthony Nolan. In fact, there are 30 times more white people than African-Caribbean people willing to donate their stem cells in this country.

"The result of this? If you're black and have leukaemia then you have less than a 20 per cent chance of finding the best possible match when your last hope of survival is a lifesaving transplant from a stranger. We are literally dying, not because a matching donor isn't out there somewhere - but because that person never joined the register.

"This isn't right, and it urgently needs to change. It's horrible to think that if my daughters needed a transplant they would be at a disadvantage because there aren't enough black and mixed race donors on the register."

Read the rest here:
David Harewood Launches Appeal For Black Stem Cell Donors

Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND
Mareen describes her outcome six months after her bone marrow stem cell treatment by Harry Adelson ND for arthritis of her hip and shoulder http://www.docereclinics.com.

By: Harry Adelson, N.D.

Excerpt from:
Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND - Video